CIBC Bancorp USA’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.5K Buy
25,547
+11,280
+79% +$12.1K ﹤0.01% 2214
2026
Q2
$16.3K Buy
14,267
+1,517
+12% +$1.81K ﹤0.01% 1920
2026
Q1
$17.7K Buy
+12,750
New +$17.5K ﹤0.01% 1741
2025
Q3
$72.8K Buy
+26,650
New +$88.7K ﹤0.01% 1387

Other funds holding AKBA

CIBC Bancorp USA's AKBA Position: Q3 2026 in Review

CIBC Bancorp USA increased its Akebia Therapeutics (AKBA) stake by 79% in Q3 2026, buying an estimated $12.1K and bringing the position to 25,547 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2214.

CIBC Bancorp USA first reported a position in AKBA in Q3 2025 and has held it in 4 quarters since. The position peaked at $72.8K in Q3 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • CIBC Bancorp USA held 25,547 shares of Akebia Therapeutics worth $23.5K as of Q3 2026.
  • CIBC Bancorp USA bought 11,280 Akebia Therapeutics shares in Q3 2026, an estimated $12.1K.
  • Akebia Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2214 holding.
  • CIBC Bancorp USA first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • CIBC Bancorp USA's Akebia Therapeutics position peaked at $72.8K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.